Corvus starts Phase 1b trial of soquelitinib in hidradenitis suppurativa patients

By Public Technologies
  • Corvus Pharmaceuticals began enrolling a Phase 1b trial of soquelitinib in hidradenitis suppurativa, expanding development beyond its current programs.
  • No results have been presented; safety and early signs of clinical benefit are expected once the 12-week treatment period is completed.
  • Study targets up to 25 adults with moderate to severe disease, aiming to support an oral option with a novel immune-modulating approach.
  • Program adds a fourth clinical indication for soquelitinib, alongside late-stage work in peripheral T cell lymphoma and mid-stage trials in atopic dermatitis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609301605PRIMZONEFULLFEED9837291) on September 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.